Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Immunic
IMUX
$219M
| $1.94M | ﹤0.01% |
15,993
+9,200
| +135% | +$936K |
|
|
SIOX
2202
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $1.93M | ﹤0.01% |
685,923
+217,800
| +47% | +$699K |
|
2203
Vanguard Dividend Appreciation ETF
VIG
$114B
| $1.93M | ﹤0.01% |
16,500
+7,000
| +74% | +$797K |
|
|
AT
2204
DELISTED
Atlantic Power Corporation
AT
| $1.93M | ﹤0.01% |
966,578
+723,024
| +297% | +$1.44M |
|
2205
Embotelladora Andina Series A
AKO.A
$3.75B
| $1.92M | ﹤0.01% |
156,600
+800
| +0.5% | +$9.29K |
|
2206
Ardmore Shipping
ASC
$719M
| $1.92M | ﹤0.01% |
442,522
-310,676
| -41% | -$1.66M |
|
2207
Alphatec Holdings
ATEC
$1.51B
| $1.92M | ﹤0.01% |
408,189
-132,390
| -24% | -$585K |
|
2208
CSP Inc
CSPI
$81.1M
| $1.92M | ﹤0.01% |
463,204
-25,630
| -5% | -$113K |
|
|
PROF
2209
Profound Medical
PROF
$241M
| $1.91M | ﹤0.01% |
112,880
-7,300
| -6% | -$92.1K |
|
2210
Diana Shipping
DSX
$309M
| $1.91M | ﹤0.01% |
1,820,545
-657,520
| -27% | -$754K |
|
2211
Transact Technologies
TACT
$53.2M
| $1.91M | ﹤0.01% |
416,897
-10,398
| -2% | -$43.6K |
|
|
CBL
2212
DELISTED
CBL& Associates Properties, Inc.
CBL
| $1.91M | ﹤0.01% |
7,000,284
+1,675,568
| +31% | +$445K |
|
2213
Aptevo Therapeutics
APVO
$4.46M
| – | – |
0
| – | – |
|
|
ATNX
2214
DELISTED
Athenex, Inc. Common Stock
ATNX
| $1.89M | ﹤0.01% |
+6,880
| New | +$1.46M |
|
2215
BRC Group Holdings
RILY
$299M
| $1.89M | ﹤0.01% |
86,839
-9,700
| -10% | -$186K |
|
|
GIFI
2216
DELISTED
Gulf Island Fabrication
GIFI
| $1.89M | ﹤0.01% |
615,013
+124,077
| +25% | +$372K |
|
2217
Standard Motor Products
SMP
$870M
| $1.89M | ﹤0.01% |
45,810
-16,490
| -26% | -$667K |
|
2218
Atlanticus Holdings
ATLC
$1.56B
| $1.88M | ﹤0.01% |
182,208
+13,600
| +8% | +$181K |
|
2219
Kingstone Companies
KINS
$285M
| $1.88M | ﹤0.01% |
425,889
+22,800
| +6% | +$108K |
|
2220
Amphenol
APH
$206B
| $1.88M | ﹤0.01% |
78,400
-1,696,000
| -96% | -$37.9M |
|
2221
Great Elm Group
GEG
$67.7M
| $1.88M | ﹤0.01% |
804,717
-1,100
| -0.1% | -$2.3K |
|
|
ADXS
2222
DELISTED
Advaxis Inc
ADXS
| $1.88M | ﹤0.01% |
3,498,918
-111,501
| -3% | -$74.9K |
|
2223
Tronox
TROX
$952M
| $1.87M | ﹤0.01% |
+258,600
| New | +$1.71M |
|
2224
iShares AAA-A Rated Corporate Bond ETF
QLTA
$1.21B
| $1.86M | ﹤0.01% |
+32,100
| New | +$1.82M |
|
2225
ACNB Corp
ACNB
$660M
| $1.85M | ﹤0.01% |
70,805
-20,105
| -22% | -$499K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.